Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research report issued on Thursday, Benzinga reports. They presently have a $45.00 target price on the stock. Needham & Company LLC’s price target indicates a potential upside of 149.58% from the company’s […]
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) General Counsel Mike Ouimette sold 4,755 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $17.55, for a total transaction of $83,450.25. Following the completion of the sale, the general counsel now owns 60,443 shares […]
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) insider Eric Lefebvre sold 22,321 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $18.01, for a total transaction of $402,001.21. Following the completion of the sale, the insider now owns 167,215 shares […]
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) shares traded up 2.2% on Thursday . The company traded as high as $18.24 and last traded at $18.21. 426,095 shares were traded during trading, a decline of 52% from the average session volume of 881,966 shares. The stock had previously closed at $17.81. Wall Street Analysts Forecast […]
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Rating) shares dropped 5% on Monday . The company traded as low as $19.68 and last traded at $19.79. Approximately 266,692 shares changed hands during trading, a decline of 69% from the average daily volume of 857,019 shares. The stock had previously closed at $20.84. Wall Street Analysts Forecast […]